{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:57:50Z","timestamp":1740128270420,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13365-018-0680-y","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T11:02:53Z","timestamp":1538996573000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir\/emtricitabine + atazanavir\/ritonavir or simplify to abacavir\/lamivudine + atazanavir"],"prefix":"10.1007","volume":"25","author":[{"given":"Kevin","family":"Robertson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-2655","authenticated-orcid":false,"given":"Lisa L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine B","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Shaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"680_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/cid\/ciw279","volume":"63","author":"A Arenas-Pinto","year":"2016","unstructured":"Arenas-Pinto A, Stohr W, Jager R, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI, PIVOT Neurocognitive sub-study Team (2016) Neurocognitive function and neuroimaging markers in virologically suppressed HIV-positive patients randomized to ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional substudy from the PIVOT trial. Clin Infect Dis 63:257\u2013264. \n                    https:\/\/doi.org\/10.1093\/cid\/ciw279","journal-title":"Clin Infect Dis"},{"key":"680_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciw399","volume":"63","author":"M Bloch","year":"2016","unstructured":"Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA (2016) A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infect Dis 63:687\u2013693. \n                    https:\/\/doi.org\/10.1093\/cid\/ciw399","journal-title":"Clin Infect Dis"},{"key":"680_CR3","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, New Jersey","edition":"2"},{"key":"680_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/QAI.0b013e318274e2b0","volume":"62","author":"A Cusini","year":"2013","unstructured":"Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, G\u00fcnthard HF, Swiss HIV Cohort Study (2013) Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 62:28\u201335. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e318274e2b0","journal-title":"J Acquir Immune Defic Syndr"},{"key":"680_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1001\/archneur.61.11.1699","volume":"61","author":"LA Cysique","year":"2004","unstructured":"Cysique LA, Maruff P, Brew BJ (2004) Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61:1699\u20131704. \n                    https:\/\/doi.org\/10.1001\/archneur.61.11.1699","journal-title":"Arch Neurol"},{"key":"680_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.acn.2005.07.011","volume":"21","author":"LA Cysique","year":"2006","unstructured":"Cysique LA, Maruff P, Darby D, Brew BJ (2006) The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 21:185\u2013194. \n                    https:\/\/doi.org\/10.1016\/j.acn.2005.07.011","journal-title":"Arch Clin Neuropsychol"},{"key":"680_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1176\/appi.neuropsych.23.1.83","volume":"23","author":"LA Cysique","year":"2011","unstructured":"Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ (2011) HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 23:83\u201389. \n                    https:\/\/doi.org\/10.1176\/jnp.23.1.jnp83","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"680_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/WNL.59.3.342","volume":"59","author":"A Luca De","year":"2002","unstructured":"De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L (2002) Correlates of independent HIV-1 replications in the CNS and of its control by antiretrovirals. Neurology 59:342\u2013347","journal-title":"Neurology"},{"key":"680_CR9","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (2018) Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at\n                           \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf\n                    \n                  . Accessed April 4, 2018"},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1310\/hct1103-170","volume":"11","author":"R Elion","year":"2010","unstructured":"Elion R, Berger D, Richmond G, Sension M, Dejesus E, Cimoch P, St Clair M, Yau L, Ha B, Col102060 Study Team (2010) Simplified maintenance therapy with abacavir\/lamivudine and atazanavir after discontinuation of ritonavir. HIV Clin Trials 11:170\u2013173. \n                    https:\/\/doi.org\/10.1310\/hct1103-170","journal-title":"HIV Clin Trials"},{"key":"680_CR11","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1097\/QAD.0b013e32834a40cd","volume":"25","author":"RJ Ellis","year":"2011","unstructured":"Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I, CHARTER Group (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747\u20131571. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32834a40cd","journal-title":"AIDS"},{"key":"680_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1310\/hct1206-333","volume":"12","author":"L Garvey","year":"2011","unstructured":"Garvey L, Surendrakumar V, Winston A (2011) Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 12:333\u2013338. \n                    https:\/\/doi.org\/10.1310\/hct1206-333","journal-title":"HIV Clin Trials"},{"key":"680_CR13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1086\/517497","volume":"44","author":"J Gatell","year":"2007","unstructured":"Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group (2007) Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 44:1484\u20131492. \n                    https:\/\/doi.org\/10.1086\/517497","journal-title":"Clin Infect Dis"},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3851\/IMP1666","volume":"15","author":"J Ghosn","year":"2010","unstructured":"Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF (2010) Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as ritonavir-boosted regimen. Antivir Ther 15:993\u20131002. \n                    https:\/\/doi.org\/10.3851\/IMP1666","journal-title":"Antivir Ther"},{"key":"680_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/01.qai.0000197077.64021.07","volume":"41","author":"ML Giancola","year":"2006","unstructured":"Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A (2006) Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 41:332\u2013337. \n                    https:\/\/doi.org\/10.1097\/01.qai.0000197077.64021.07","journal-title":"J Acquir Immune Defic Syndr"},{"key":"680_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1567205010666131212110148","volume":"11","author":"RA Grove","year":"2014","unstructured":"Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer\u2019s disease. Curr Alzheimer Res 11:47\u201358","journal-title":"Curr Alzheimer Res"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10461-017-1683-z","volume":"22","author":"LJ Haddow","year":"2017","unstructured":"Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, Gerstoft J, Nielsen L, Vassilenko A, Collins S, Rodger AJ, Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group (2017) Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav 22:1573\u20131583. \n                    https:\/\/doi.org\/10.1007\/s10461-017-1683-z","journal-title":"AIDS Behav"},{"key":"680_CR18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087\u20132096. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e318200d727","journal-title":"Neurology"},{"key":"680_CR19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","volume":"23","author":"CM Marra","year":"2009","unstructured":"Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, AIDS Clinical Trials Group 736 Study Team (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359\u20131366. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32832c4152","journal-title":"AIDS"},{"key":"680_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/arclin\/acp010","volume":"24","author":"P Maruff","year":"2009","unstructured":"Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165\u2013178. \n                    https:\/\/doi.org\/10.1093\/arclin\/acp010","journal-title":"Arch Clin Neuropsychol"},{"key":"680_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1089\/aid.2007.0310","volume":"24","author":"JA Munoz-Moreno","year":"2008","unstructured":"Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, P\u00e9rez-Alvarez N, Molt\u00f3 J, G\u00f3mez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retrovir 24:1301\u20131307. \n                    https:\/\/doi.org\/10.1089\/aid.2007.0310","journal-title":"AIDS Res Hum Retrovir"},{"key":"680_CR22","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/jac\/dkr316","volume":"66","author":"J Pavie","year":"2011","unstructured":"Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM, NEAT Unboosted Atazanavir Cohort Study Group (2011) Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virologic suppression under antiretroviral therapy. J Antimicrob Chemother 66:2372\u20132378. \n                    https:\/\/doi.org\/10.1093\/jac\/dkr316","journal-title":"J Antimicrob Chemother"},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/00126334-200405010-00003","volume":"36","author":"KR Robertson","year":"2004","unstructured":"Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36:562\u2013566","journal-title":"J Acquir Immune Defic Syndr"},{"key":"680_CR24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/QAD.0b013e32828e4e27","volume":"21","author":"KR Robertson","year":"2007","unstructured":"Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915\u20131921. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32828e4e27","journal-title":"AIDS"},{"key":"680_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1097\/QAD.0000000000001189","volume":"30","author":"KR Robertson","year":"2016","unstructured":"Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO, AIDS Clinical Trials Group (ACTG) 5303 team (2016) Neurocognition with maraviroc compared with tenofovir in HIV. AIDS 30:2315\u20132321. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001189","journal-title":"AIDS"},{"key":"680_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1310\/hct1003-129","volume":"10","author":"JR Santos","year":"2009","unstructured":"Santos JR, Molto J, Llibre JM, P\u00e9rez N, Capit\u00e1n MC, Clotet B (2009) Unboosted atazanavir plus co-formulated lamivudine\/abacavir as a ritonavir-sparing simplification study in routine clinical practice. HIV Clin Trials 10:129\u2013134. \n                    https:\/\/doi.org\/10.1310\/hct1003-129","journal-title":"HIV Clin Trials"},{"key":"680_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrneurol.2016.27","volume":"12","author":"D Saylor","year":"2016","unstructured":"Saylor D, Dickens A, Sacktor N Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder- pathogenesis and prospects for treatment. Nat Rev Neurol 12:234\u2013248. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2016.27","journal-title":"Nat Rev Neurol"},{"key":"680_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/QAI.0b013e3181a5701c","volume":"51","author":"M Sension","year":"2009","unstructured":"Sension M, de Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, Gonz\u00e1lez-Garc\u00eda J, Donnelly A, Phiri P, Ledesma E, McGrath D, 067 Study Group (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51:153\u2013162. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e3181a5701c","journal-title":"J Acquir Immune Defic Syndr"},{"key":"680_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283354a7b","volume":"24","author":"S Simioni","year":"2010","unstructured":"Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243\u20131250. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e3283354a7b","journal-title":"AIDS"},{"key":"680_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/QAD.0b013e32834171f8","volume":"25","author":"M Smurzynski","year":"2011","unstructured":"Smurzynski M, Wu K, Letentdre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25:357\u2013365. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32834171f8","journal-title":"AIDS"},{"key":"680_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jac\/dkm413","volume":"61","author":"V Soriano","year":"2008","unstructured":"Soriano V, Garcia-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Mart\u00edn-Carbonero L, Rodr\u00edguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, Gonz\u00e1lez-Lahoz J (2008) Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viremia: final results of the SLOAT trial. J Antimicrob Chemother 61:200\u2013205. \n                    https:\/\/doi.org\/10.1093\/jac\/dkm413","journal-title":"J Antimicrob Chemother"},{"key":"680_CR32","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1097\/QAD.0b013e32833bee1b","volume":"24","author":"KE Squires","year":"2010","unstructured":"Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS, ARIES study team (2010) Similar efficacy and tolerability of atazanavir compared with atazanavir\/ritonavir, each with abacavir\/lamivudine after initial suppression with abacavir\/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 24:2019\u20132027. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32833bee1b","journal-title":"AIDS"},{"key":"680_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1086\/650743","volume":"50","author":"A Winston","year":"2010","unstructured":"Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA, Altair Study Group (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-na\u00efve, HIV-1\u2013infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50:920\u2013929. \n                    https:\/\/doi.org\/10.1086\/650743","journal-title":"Clin Infect Dis"},{"key":"680_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061949","volume":"8","author":"A Winston","year":"2013","unstructured":"Winston A, Arenas-Pinto A, Stohr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI, PIVOT Trial Team (2013) Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 8:e61949. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0061949","journal-title":"PLoS One"},{"key":"680_CR35","doi-asserted-by":"publisher","first-page":"e0118608","DOI":"10.1371\/journal.pone.0118608","volume":"10","author":"A Winston","year":"2015","unstructured":"Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA, ALTAIR Study Group (2015) Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. PLoS One 10:e0118608. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0118608","journal-title":"PLoS One"},{"key":"680_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096187","volume":"9","author":"DA Wohl","year":"2014","unstructured":"Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2014) Simplification to abacavir\/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One 9:e96187. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0096187","journal-title":"PLoS One"},{"key":"680_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/hiv.12281","volume":"17","author":"DA Wohl","year":"2016","unstructured":"Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2016) The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir\/lamivudine\u2009+\u2009atazanavir. HIV Med 17:106\u2013117. \n                    https:\/\/doi.org\/10.1111\/hiv.12281","journal-title":"HIV Med"},{"key":"680_CR38","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2013.s1.e8","volume":"5","author":"L Zhou","year":"2013","unstructured":"Zhou L, Saksena NK (2013) HIV associated neurocognitive disorders. Infect Dis Rep 5:e8. \n                    https:\/\/doi.org\/10.4081\/idr.2013.s1.e8","journal-title":"Infect Dis Rep"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0680-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T19:25:36Z","timestamp":1570476336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0680-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0680-y","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"type":"print","value":"1355-0284"},{"type":"electronic","value":"1538-2443"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"19 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent to participate in the study, and the protocol was approved by the institutional review board for each study site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Funding for this study was provided by ViiV Healthcare. During the conduct of the study, K.R. received consultancy fees and\/or research funding from GlaxoSmithKline and ViiV Healthcare. P.M. is an employee of Cogstate Ltd. D.A.W. participated in advisory boards convened by Gilead Sciences and Janssen Therapeutics. Merck and Co., Gilead Sciences, and GlaxoSmithKline have provided the University of North Carolina with funding for his research. C.B.S. received consultancy fees and\/or research funding from GlaxoSmithKline, ViiV Healthcare, Merck, Schering-Plough, and Abbott. H.E. is an employee of the Alameda Health System\/Highland Hospital. L.L.R. and M.S.S. are employees of ViiV Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"L.L.R and M.S.S. are both employees of ViiV Healthcare; P.M. is an employee of Cogstate. K.R. and H.E. have no conflicts of interest. C.B.S. has received consultancy fees and\/or research funding from GlaxoSmithKline and ViiV Healthcare. GlaxoSmithKline has provided the University of North Carolina at Chapel Hill with funding for D.A.W.\u2019s research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}